Biosimilars

Latest News

Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US
Biocon reaches settlement agreement with Regeneron to launch aflibercept biosimilar, Yesafili, in the US

April 15th 2025

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

UK MHRA issues approval for aflibercept biosimilar FYB203 (AHZANTIVE) from Formycon
UK MHRA issues approval for aflibercept biosimilar FYB203 (AHZANTIVE) from Formycon

February 25th 2025

Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06

February 18th 2025

CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars
CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars

February 3rd 2025

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

January 13th 2025

Latest CME Events & Activities

Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data

View More

Practical Approaches to Modern Dry Eye Treatment and Management

June 25, 2025

Register Now!

Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy

View More

Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease

View More

Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)

View More

Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)

View More

Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)

View More

Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)

View More

Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)

View More

Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)

View More

Retina Specialists: Join us in Long Beach

July 31, 2025 - August 2, 2025

Register Now!

SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application

View More

Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

View More

3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between

September 6, 2025

Register Now!

Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D

View More

EyeCon 2025

September 26-27, 2025

Register Now!

Optometrists: Earn COPE CE Credits in Portland or Virtually

October 16-17, 2025

Register Now!

Join us at The Ophthalmology Meeting in Orlando this October

October 18, 2025

Register Now!

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)

View More

Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)

View More

Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Expert Perspectives on Technological Advances in Cataract Surgery

View More

Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy

View More

Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy

View More

(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes

View More

Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs

View More

(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention

View More

More News

© 2025 MJH Life Sciences

All rights reserved.